Compare Abeona Therapeutics Inc (ABEO) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares Self-Driving EV and Tech — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while iShares Self-Driving EV and Tech trades at $37.18. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.
| ABEO | IDRV | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.45 | $45.48 |
52-Week Low | $4.17 | $34.49 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
IDRV trades at $37.18, down 0.51% today, with a bullish technical signal from moving averages and key indicators like the ADX suggesting a strong trend. Support levels are firm near $35–$37, while resistance sits at $38–$39. Recent news highlights rising global EV sales, with growth in Europe and China, though U.S. adoption lags. The company has a dividend scheduled for June 2026.
The outlook for IDRV is cautiously optimistic, driven by sector tailwinds from EV adoption and regulatory support. Key risks include competitive pressures from Chinese automakers and sensitivity to fuel price volatility. Analyst sentiment is mixed, with technical strength offset by fundamental data gaps. Investors should monitor upcoming earnings for margin trends and guidance updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →
